1 |
SYNTHESIS AND NMR STUDIES OF PERI-SUBSTITUTED PROMAZINE AND IMIPRAMINE ANALOGUES.Hintermeister, Nalukui Mwisiya. January 1984 (has links)
No description available.
|
2 |
The pharmacokinetics of imipramine in Chinese subjectsChen, An Ge January 1999 (has links)
No description available.
|
3 |
An electrophysiological and neuropharmacological study of sibutramine hydrochloride and its metabolitesMahony, Mary Teresa January 1990 (has links)
No description available.
|
4 |
An evaluation of a brief psychological treatment for major depression in primary careMynors-Wallis, Laurence Mark January 1994 (has links)
No description available.
|
5 |
The evaluation of melatonin as a possible antidepressiveSkene, Debra Jean January 1980 (has links)
Melatonin, a hormone of the pineal gland, was evaluated in a variety of animal models of depression. Measurements of the frog righting reflex and rat locomotor activity showed that low doses of melatonin have a serotonin-like potentiating effect following monoamine oxidase inhibition. High doses of melatonin caused a reduction in the duration of rat immobility in the Porsolt model of depression and exerted a chlorpromazine-like effect on conditioned avoidance behaviour. In view of the indoleamine hypothesis of depressive disorders, the possibility of melatonin being a potential antidepressive is discussed and it is concluded that melatonin might be useful in the treatment of "agitated" depressions
|
6 |
An investigation into the possible neuroprotective role of antidepressant drugsSteiner, Claire January 2002 (has links)
Antidepressants are widely used in the treatment of depressive illnesses associated with neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease and Huntington’s disease. Neuroprotection in such disorders is of vital importance in order to delay the progression of the primary disorder. The pathology of neurodegeneration is not fully understood. It is however widely accepted that oxidative stress and excitotoxicity play a major role. Brain tissue is rich in phospholipids, which are especially prone to oxidation due to the high level of oxygen utilization in the brain. In addition, the brain lacks defence mechanisms to protect it against the wrath of free radicals. Presently, there is a wide variety of antidepressant drugs available. These range from the original tricyclic antidepressants to the newer selective serotonin reuptake inhibitors. It is not known whether antidepressant drugs, old or new, offer neuroprotection or how the existing state and/or the progression of neurodegeneration, is influenced by these agents. The present study was undertaken to determine how nortriptyline, trimipramine and fluoxetine affect neurodegeneration. Initial in vitro and in vivo studies show that all three of the antidepressants (0-1mM) studied provide neuroprotection from quinolinic acid induced lipid peroxidation. A histological investigation supported these findings by showing that a marginal degree of neuroprotection is apparent when treating animals with antidepressants (10mg/kg) before and following quinolinic acid intrastriatal injection. Further studies were undertaken in an attempt to determine the mode of neuroprotective action of the agents studied. An in vitro study of superoxide anion induced lipid peroxidation indicates that these agents do not act as antioxidants. The influence of the antidepressants on tryptophan 2,3-dioxygenase activity was assessed, based on the understanding that inhibition of this enzyme results in increased levels of the known antioxidant indoleamine, melatonin. Nortriptyline hydrochloride is seen to inhibit tryptophan 2,3-dioxygenase activity and as such it is possible that this antidepressant can indirectly provide neuroprotection by increasing available melatonin. Electrochemical and UV/visible studies show that trimipramine maleate interacts with free iron (II) and iron (III) ions. Free metal ions can catalyse the formation of damaging free radicals. Through interaction with trimipramine maleate, these ions will be unavailable to the system and thus cannot contribute to oxidative stress. The findings of this study indicate that antidepressants may be able to provide neuroprotection to neuronal cells. The mode of such neuroprotective actions need to be further examined so that patients suffering from depression coexisting with neurodegenerative diseases can be safely and effectively treated.
|
7 |
A rhetorical tale : neurochemistry and the efficacies of antidepressants in CanadaCuffe, Jennifer January 2002 (has links)
Recent work in anthropology has speculated on how developments in molecular biology and medicine might bring about new bodies, selves, and forms of sociality. This thesis explores how herbal and pharmaceutical antidepressants differently affect experiences of one's neurochemistry. It does so in two ways. First, it outlines the historical 'social life' of pharmaceutical antidepressants, including their co-production with depression, and the neurochemical body in a particular style of reasoning in biological psychiatry. Second, it presents and analyzes claims made for the efficacy of antidepressants made in vernacular North American books, advertisements, and pamphlets. Although the claims for both herbal and pharmaceutical antidepressants allude to the same realms of value---those of science, nature/history, and personal experience---their different social lives enable different access to the neurochemical body.
|
8 |
A rhetorical tale : neurochemistry and the efficacies of antidepressants in CanadaCuffe, Jennifer January 2002 (has links)
No description available.
|
9 |
The effect of psychotropic medication on sleep and daytime sleepiness in volunteers and depressed patientsWilson, Susan Jenifer January 1999 (has links)
No description available.
|
10 |
Rapid symptomatic treatment in major depression : clinical, pharmacological and economic aspects of a novel regimeTome de la Granja, Maria Begona January 1997 (has links)
No description available.
|
Page generated in 0.0236 seconds